Alnylam Pharmaceuticals ALNY OXLUMO — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's oxlumo — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's OXLUMO — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported OXLUMO — total revenues of $52.12M in Q2 2026.
- How has Alnylam Pharmaceuticals's OXLUMO — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's OXLUMO — total revenues increased by 11.2% year-over-year, from $46.87M to $52.12M.
- What is the long-term trend for Alnylam Pharmaceuticals's OXLUMO — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's OXLUMO — total revenues has grown at a 33.9% compound annual growth rate (CAGR), from $59.59M to $191.44M.
- What does OXLUMO — total revenues mean?
- This metric represents the total gross revenue generated from the commercial sale of a specific therapeutic product within the company's portfolio. It reflects the market adoption, pricing power, and patient demand for this particular RNAi-based treatment. Monitoring this figure helps investors assess the product's lifecycle stage and its contribution to the company's overall top-line growth.